L-TIL in Patients With Malignancy Resistance to Anti-PD-1 Therapy
Safety and effectiveness of liquid tumor infiltrating lymphocytes in patients with advanced malignant tumors who have failed to anti-PD-1 therapy
Advanced Solid Tumor
BIOLOGICAL: liquid tumor infiltrating lymphocytes
the rate of reverse events, the rate of reverse events, three months
clinical benefit rate, the proportion of patients benefit from liquid tumor infiltrating lymphocytes, three months|time to progression, from the date of therapy to the first date of determined progressive disease, six months
Safety and effectiveness of liquid tumor infiltrating lymphocytes in patients with advanced malignant tumors who have failed to anti-PD-1 therapy